Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutch-Belgian pediatric AML protocol with reduced anthracycline exposure
NL-OMON28546Not yet recruiting
- Sponsor
- SKion
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cytarabine and etoposide in acute myeloid leukemia (AML), sponsored by SKion. Primary endpoints: International pediatric AML treatment feasibility and outcome, Reduction of cumulative anthracycline exposure and 2 more. Planned start Feb 2010; status: not yet recruiting.
02
Drugs
cytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON28546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28546.